Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic pooled fecal microbiota
- Development stage
- Unknown
- Lead developer
- Gustave Roussy
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Allogeneic pooled fecal microbiota is an investigational live biotherapeutic product developed by the Institut Gustave Roussy for the treatment of non-small cell lung cancer (NSCLC). It consists of a standardized, high-diversity consortium of live bacteria collected and pooled from multiple healthy donors to ensure a broad and robust microbial profile. The primary mechanism of action involves the modulation of the patient's gut microbiome to reverse dysbiosis and stimulate the host immune system. By restoring a responder microbial phenotype, the therapy is intended to enhance the efficacy of immune checkpoint inhibitors (such as PD-1/PD-L1 blockers) in patients who are otherwise non-responsive or have developed resistance. The pooled nature of the product aims to provide greater taxonomic richness and consistency compared to single-donor fecal microbiota transplantation (FMT).
- Other names
- pooled fecal microbiota transplantallogeneic pooled FMTpooled FMT
Beyond the preview
Go deeper on allogeneic pooled fecal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic pooled fecal microbiota.